MAQUET and Swisstom are pleased to announce their distribution partnership for the monitoring and diagnostic product Swisstom BB2
Acute Lung Injury is still a leading cause of death for intensive care patients. Swisstom BB2 was especially developed to continuously monitor lung function of ICU patients undergoing mechanical ventilation. It offers direct visualisation of lung aeration at the bedside complementing highly performant MAQUET SERVO ventilators, which have a long history in helping clinicians implement protective ventilation strategies. Now the positive effects of Neurally Adjusted Ventilatory Assist (NAVA®) can be traced at the bedside with this real-time
Electrical Impedance Tomography (EIT). This monitoring of ventilated patients is completely radiation-free. Therefore, Swisstom BB2 can be used continuously for several days.
“Understanding what really happens in the lungs during mechanical ventilation is still very challenging today”, says Serge Exshaw, Vice President MAQUET Holding and Head of Global Sales and Marketing. MAQUET already developed tools including measured tidal volume per kilogram of predicted body weight in the new SERVO-U. “However seeing the lung aeration continuously and in real-time represents a step further for individual adaptation to patient condition”, he emphasises. “We are really delighted about this partnership with Swisstom.”
MAQUET is one of the leading companies in critical care diagnostics and therapies. With its well-known brands like intensive care ventilators SERVO-i® or the new SERVO-UTM and NAVA®, the company offers a wide range of therapeutic options to treat all patient categories including the sickest ones.
“Swisstom is proud to start a distribution partnership with MAQUET in Western Europe. The broad product portfolio and the excellent clinical knowhow of the MAQUET team combined with Swisstom’s cutting edge technology will provide brand new solutions for hospitals”, says Josef X. Brunner, Swisstom’s CEO.
Source: Swisstom
18 March 2014
